ABSTRACT

Introduction

Metastatic triple-negative breast cancers (mTNBC) are characterized by aggressive behavior and worse clinical outcomes than other breast cancer subtypes, as well as poor response to cytotoxic chemotherapies. The use of antibody-drug conjugates (ADCs) has been investigated as a potential treatment strategy, particularly in heavily pretreated disease.

Areas covered

This article reviews the preclinical and clinical data supporting the use of the ADCs sacituzumab govitecan (SG), ladiratuzumab vedotin (LV), and trastuzumab deruxtecan (T-DXd) in mTNBC, and highlights ongoing clinical trials and future clinical applications.

Expert opinion

SG, LV, and T-DXd have demonstrated their potential to meaningfully improve clinical outcomes in patients with pretreated mTNBC, as demonstrated by notable response rates in phase I/II and, for SG, phase III clinical trials. Investigation of their use in combination with other agents, including PARP inhibitors and checkpoint inhibitors, is ongoing in the metastatic setting, and their application in early-stage TNBCs are under investigation. ADCs are therefore expected to redefine treatment paradigms in TNBC.

中文翻译：

---

转移性三阴性乳腺癌中的抗体-药物偶联物：关注 sacituzumab govitecan、ladiratuzumab vedotin 和 trastuzumab deruxtecan

摘要

介绍

与其他乳腺癌亚型相比，转移性三阴性乳腺癌 (mTNBC) 的特征是具有攻击性行为和更差的临床结果，以及对细胞毒性化学疗法的不良反应。抗体-药物偶联物 (ADC) 的使用已作为一种潜在的治疗策略进行了研究，特别是在经过大量预处理的疾病中。

涵盖的领域

本文回顾了支持在 mTNBC 中使用 ADC sacituzumab govitecan (SG)、ladiratuzumab vedotin (LV) 和 trastuzumab deruxtecan (T-DXd) 的临床前和临床数据，并重点介绍了正在进行的临床试验和未来的临床应用。

专家意见

SG、LV 和 T-DXd 已证明它们有潜力显着改善经预处理的 mTNBC 患者的临床结果，这在 I/II 期和 SG 的 III 期临床试验中的显着缓解率证明了这一点。在转移性环境中，正在研究它们与其他药物（包括 PARP 抑制剂和检查点抑制剂）的联合使用，并且它们在早期 TNBC 中的应用正在研究中。因此，预计 ADC 将重新定义 TNBC 的治疗模式。